View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Galapagos Media reports Paul Stoffels behind non-binding offer for cel...

According to media reports, Paul Stoffels, Galapagos' previous CEO, has assembled a group of investors to bid for the company's cell therapy business. After joining Galapagos in 2022, Paul Stoffels pivoted the company towards cell therapies and focussed the company's efforts on de-centralised CAR-T manufacturing as a way to broaden access to such treatments. Following his resignation earlier this year, he now has placed a non-binding offer for the cell therapy business which is under strategic r...

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Galapagos Receives non-binding offers for cell therapy business

Galapagos announced that it has received a limited number of non-binding offers from consortia, predominantly comprised of financial investors, to acquire the cell therapy business. The deadline for potential bidders to put forward binding, fully-financed, offers is in the coming weeks. The company will make an announcement on the outcome of the review of strategic alternatives for the cell therapy business no later than its 3Q25 update on 5 November 2025. € 37 TP and ACCUMULATE reiterated.

Guy Sips ... (+8)
  • Guy Sips
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update October: Removing VGP – Adding Shurgard a...

In this October update of our Dynamic Top Pick List we are removing VGP while adding Shurgard and Wolters Kluwer. Since its recent inclusion in our Dynamic Top Pick List in July-25, VGPs share rose by 10.6%. While we still believe there is significant upside to the share price, we don't see short term catalysts. In fact, the macro picture remains cloudy with the jury still out on the impact of tariffs and the erratic US policy shifts. Also, we are a bit concerned that competition in Western Eur...

 PRESS RELEASE

Galapagos Provides Update on Strategic Alternatives for Its Cell Thera...

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business   Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business (the “Cell Therapy Business”), including a potential divestiture of the Cell Therapy Business, with the goal of preserving shareholder value. As part of its review of strategic alternatives, over ...

 PRESS RELEASE

Galapagos geeft update over strategische alternatieven voor haar celth...

Galapagos geeft update over strategische alternatieven voor haar celtherapieactiviteiten Mechelen, België; 1 oktober 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) en haar Raad van Bestuur hebben vandaag de volgende verklaring uitgegeven: Op 13 mei 2025 kondigde Galapagos aan dat haar Raad van Bestuur (de “Raad”) had besloten om alle strategische alternatieven voor haar celtherapieactiviteiten (de “Celtherapieactiviteiten”) te verkennen, met inbegrip van een mogelijke verkoop van de Celtherapieactiviteiten, met als doel het waarborgen van aandeelhouderswaarde.   Als onderdeel...

Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Wim Lewi
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aedifica: €21m investment in the development of 3 care homes in Finland. CTP: Highlights from 2-day CMD in Germany. dsm-firmenich: Softly does it. Prosus: Expanding the ecosystem. Randstad: Preliminary preview 3Q25F results due 22 October. TKH Group: Change is coming. UCB: Renewed tariff threat on US branded pharma unlikely to affect UCB

Konrad Zomer
  • Konrad Zomer
Konrad Zomer
  • Konrad Zomer
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Belgian telcos: Football rights negotiations between DAZN and Proximus resume. Eurocommercial Properties: CMD Feedback. EVS: Adds another small acquisition to its new ‘media robotics' segment. Kinepolis: Paramount Skydance reportedly to bid for Warner Bros. Discovery. Wolters Kluwer: Two CEOs, one strong AI story

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch